SCHEMBL15050849

SCHEMBL15050849

Cc1cnc(N)cc1-n1cc(-c2ncn(COCC[Si](C)(C)C)n2)c(-c2cc(CN3CCCC3)ccc2Cl)n1

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 3/20 0.34
S1PR1 P21453 1/20 0.32
HRH3 Q9Y5N1 1/20 0.31
DCTPP1 Q9H773 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051384 0.89 DGAT1 (0.34) KLKB1HRH3GAA
SCHEMBL15051198 0.88 WDR5 (0.34) KLKB1HRH3GAA
SCHEMBL15072595 0.87 DGAT1 (0.34) KLKB1HRH3GAA
SCHEMBL626542 0.74 HSP90AA1 (0.33) KLKB1HRH3GAA
SCHEMBL15051135 0.73
SCHEMBL15051241 0.72 P2RX7 (0.35)
SCHEMBL15051305 0.69 DGAT1 (0.36)
SCHEMBL15051746 0.69 GAA (0.39) HRH3GAA
SCHEMBL15072422 0.68 GAA (0.38) HRH3GAA
SCHEMBL15050831 0.67 ALDH1A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 KLKB1 4607/4885S1PR1 2905/4885HRH3 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.